Tandem Diabetes (TNDM) Tops Q3 EPS by 1c ; Offers Guidance

Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.31), $0.01 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $249.25 million versus the consensus estimate of $237.11 million.

GUIDANCE:

Tandem Diabetes sees FY2025 revenue of ~$1 billion, versus the consensus of $1.002 billion.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• TD Cowen: '2Q26 Digital Ad Expert Call: Resilient Consumer Continues to Drive Ad Spend'
• Gas prices fall 46 cents from April highs but consumer confidence still hits decade low, missing forecasts
• Bridgeline Digital reaches 25th HawkSearch deployment this fiscal year